Drug Trial Radar · NCT01374490
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Last checked: Nov 19, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Jun 7, 2011
Primary completion
Oct 31, 2012
Study completion Oct 31, 2012
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.
Conditions
- HIV Enteropathy
- Diarrhea With HIV
Interventions
CrofelemerDrug
Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).Time frame: 48 weeks
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Bakersfield, California
Site not named
Beverly Hills, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
Fort Lauderdale, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
Wilton Manors, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Detroit, Michigan
Site not named
Santa Fe, New Mexico
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Cincinnati, Ohio
Site not named
Portland, Oregon
Site not named
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.